Nutritional Advice El Mondo
Objectives:
Does low-dose aspirin during or prior to hospitalization reduce mortality in COVID-19 patients?
Study design:
This review article included 6 studies, comprising of 13,993 COVID-19 patients.
The studies had a low-moderate risk of bias based on Newcastle-Ottawa Scale.
Funnel plot analysis showed slight asymmetry and after non-parametric trim-and-fill analysis (linear 0 estimator, right side), the pooled effect estimate remained significant [RR = 0.48, 95% CI = 0.36 to 0.65]. Egger’s test was not significant for small-study effects [p = 0.777].
Results and conclusions:
The investigators found meta-analysis indicated that low-dose aspirin use was independently and significantly associated with a reduced mortality risk of 54% in COVID-19 patients [RR = 0.46, 95% CI = 0.35 to 0.61, p 0.001, I2 = 36.2%].
The investigators found subgroup analysis on in-hospital low-dose aspirin administration also showed statistically significant mortality reduction [RR = 0.39, 95% CI = 0.16 to 0.96, p 0.001, I2 = 47.0%].
The investigators concluded low-dose aspirin use is independently associated with reduced mortality in patients with COVID-19 with a low certainty of evidence.
Original title:
Active Prescription of Low-dose Aspirin During or Prior to Hospitalization and Mortality in COVID-19 - A Systematic Review and Meta-analysis of Adjusted Effect Estimates by Martha JW, Pranata R, […], Akbar MR.
Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123385/
Additional information of El Mondo:
Find more information/studies on coronavirus right here.
Heart attack and stroke survivors are recommended to regularly take low-dose aspirin for secondary prevention. Recommended in all patients ≥ 50 years of age.